187 related articles for article (PubMed ID: 19825954)
1. Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts.
Francia G; Man S; Lee CJ; Lee CR; Xu P; Mossoba ME; Emmenegger U; Medin JA; Kerbel RS
Clin Cancer Res; 2009 Oct; 15(20):6358-66. PubMed ID: 19825954
[TBL] [Abstract][Full Text] [Related]
2. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
3. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts.
du Manoir JM; Francia G; Man S; Mossoba M; Medin JA; Viloria-Petit A; Hicklin DJ; Emmenegger U; Kerbel RS
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):904-16. PubMed ID: 16467105
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.
Orlando L; Cardillo A; Ghisini R; Rocca A; Balduzzi A; Torrisi R; Peruzzotti G; Goldhirsch A; Pietri E; Colleoni M
BMC Cancer; 2006 Sep; 6():225. PubMed ID: 16978400
[TBL] [Abstract][Full Text] [Related]
5. Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM).
Orlando L; Lorusso V; Giotta F; Di Maio M; Schiavone P; Fedele P; Quaranta A; Caliolo C; Ciccarese M; Cinefra M; Romito S; Pisconti S; Prete SD; Aieta M; Rizzi D; Maiello E; Colucci G; Cinieri S
Breast; 2020 Oct; 53():18-22. PubMed ID: 32540553
[TBL] [Abstract][Full Text] [Related]
6. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy.
Munoz R; Man S; Shaked Y; Lee CR; Wong J; Francia G; Kerbel RS
Cancer Res; 2006 Apr; 66(7):3386-91. PubMed ID: 16585158
[TBL] [Abstract][Full Text] [Related]
7. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.
Konecny GE; Pegram MD; Venkatesan N; Finn R; Yang G; Rahmeh M; Untch M; Rusnak DW; Spehar G; Mullin RJ; Keith BR; Gilmer TM; Berger M; Podratz KC; Slamon DJ
Cancer Res; 2006 Feb; 66(3):1630-9. PubMed ID: 16452222
[TBL] [Abstract][Full Text] [Related]
8. First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial.
Untch M; Muscholl M; Tjulandin S; Jonat W; Meerpohl HG; Lichinitser M; Manikhas AG; Coumbos A; Kreienberg R; du Bois A; Harbeck N; Jackisch C; Müller V; Pauschinger M; Thomssen C; Lehle M; Catalani O; Lück HJ
J Clin Oncol; 2010 Mar; 28(9):1473-80. PubMed ID: 20177030
[TBL] [Abstract][Full Text] [Related]
9. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction.
Warburton C; Dragowska WH; Gelmon K; Chia S; Yan H; Masin D; Denyssevych T; Wallis AE; Bally MB
Clin Cancer Res; 2004 Apr; 10(7):2512-24. PubMed ID: 15073131
[TBL] [Abstract][Full Text] [Related]
10. Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.
Tang TC; Man S; Lee CR; Xu P; Kerbel RS
Neoplasia; 2010 Mar; 12(3):264-74. PubMed ID: 20234820
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
Man S; Bocci G; Francia G; Green SK; Jothy S; Hanahan D; Bohlen P; Hicklin DJ; Bergers G; Kerbel RS
Cancer Res; 2002 May; 62(10):2731-5. PubMed ID: 12019144
[TBL] [Abstract][Full Text] [Related]
12. Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion.
Muñoz R; Hileeto D; Cruz-Muñoz W; Wood GA; Xu P; Man S; Viloria-Petit A; Kerbel RS
PLoS One; 2019; 14(9):e0222580. PubMed ID: 31536574
[TBL] [Abstract][Full Text] [Related]
13. Targeted prodrug treatment of HER-2-positive breast tumor cells using trastuzumab and paclitaxel linked by A-Z-CINN Linker.
Gilbert CW; McGowan EB; Seery GB; Black KS; Pegram MD
J Exp Ther Oncol; 2003; 3(1):27-35. PubMed ID: 12724856
[TBL] [Abstract][Full Text] [Related]
14. Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy.
Fujimoto-Ouchi K; Sekiguchi F; Yamamoto K; Shirane M; Yamashita Y; Mori K
Cancer Chemother Pharmacol; 2010 Jul; 66(2):269-76. PubMed ID: 19904537
[TBL] [Abstract][Full Text] [Related]
15. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.
Scheuer W; Friess T; Burtscher H; Bossenmaier B; Endl J; Hasmann M
Cancer Res; 2009 Dec; 69(24):9330-6. PubMed ID: 19934333
[TBL] [Abstract][Full Text] [Related]
16. Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278).
Guarneri V; Frassoldati A; Bruzzi P; D'Amico R; Belfiglio M; Molino A; Bertetto O; Cascinu S; Cognetti F; Di Leo A; Pronzato P; Crinó L; Agostara B; Conte P
Clin Breast Cancer; 2008 Oct; 8(5):453-6. PubMed ID: 18952561
[TBL] [Abstract][Full Text] [Related]
17. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy.
Burstein HJ; Lieberman G; Slamon DJ; Winer EP; Klein P
Ann Oncol; 2005 Nov; 16(11):1772-7. PubMed ID: 16150805
[TBL] [Abstract][Full Text] [Related]
18. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.
Klos KS; Zhou X; Lee S; Zhang L; Yang W; Nagata Y; Yu D
Cancer; 2003 Oct; 98(7):1377-85. PubMed ID: 14508823
[TBL] [Abstract][Full Text] [Related]
19. A new model of patient tumor-derived breast cancer xenografts for preclinical assays.
Marangoni E; Vincent-Salomon A; Auger N; Degeorges A; Assayag F; de Cremoux P; de Plater L; Guyader C; De Pinieux G; Judde JG; Rebucci M; Tran-Perennou C; Sastre-Garau X; Sigal-Zafrani B; Delattre O; Diéras V; Poupon MF
Clin Cancer Res; 2007 Jul; 13(13):3989-98. PubMed ID: 17606733
[TBL] [Abstract][Full Text] [Related]
20. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.
Dellapasqua S; Bertolini F; Bagnardi V; Campagnoli E; Scarano E; Torrisi R; Shaked Y; Mancuso P; Goldhirsch A; Rocca A; Pietri E; Colleoni M
J Clin Oncol; 2008 Oct; 26(30):4899-905. PubMed ID: 18794539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
